Discontinued — last reported Q3 '25
Impairment Charges
McKesson Impairment Charges increased by 200.0% to $6.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 14.3%, from $7.00M to $6.00M. Over 3 years (FY 2022 to FY 2025), Impairment Charges shows a downward trend with a -17.6% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase signals potential operational issues, poor past investment decisions, or adverse market conditions for specific business units.
Detailed definition
These are non-cash charges recorded when the carrying value of an asset exceeds its fair market value. They indicate tha...
Peer comparison
Often seen during restructuring or economic downturns across industrial sectors.
impairment_charges_cfHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $104.00M | $23.00M | $1.00M | $47.00M | $0.00 | $11.00M | $2.00M | $59.00M | $28.00M | $0.00 | $0.00 | $15.00M | $3.00M | $73.00M | $7.00M | $15.00M | $2.00M | $2.00M | $6.00M |
| QoQ Change | — | -77.9% | -95.7% | >999% | -100.0% | — | -81.8% | >999% | -52.5% | -100.0% | — | — | -80.0% | >999% | -90.4% | +114.3% | -86.7% | +0.0% | +200.0% |
| YoY Change | — | — | — | — | -100.0% | -52.2% | +100.0% | +25.5% | — | -100.0% | -100.0% | -74.6% | -89.3% | — | — | +0.0% | -33.3% | -97.3% | -14.3% |
Business Segments
| Segment | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q3 '24 |
|---|---|---|---|---|---|---|---|---|
| U.S. Pharmaceutical | — | — | — | — | — | — | — | $63.00M |
| International | $175.00M | $175.00M | $175.00M | $175.00M | $175.00M | $175.00M | $175.00M | — |
| Total | $11.00M | $2.00M | $59.00M | $28.00M | $0.00 | $0.00 | $15.00M | $73.00M |
International, U.S. Pharmaceutical were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Impairment Charges at Other Companies
Frequently Asked Questions
- What is McKesson's impairment charges?
- McKesson (MCK) reported impairment charges of $6.00M in Q4 2025.
- How has McKesson's impairment charges changed year-over-year?
- McKesson's impairment charges decreased by 14.3% year-over-year, from $7.00M to $6.00M.
- What is the long-term trend for McKesson's impairment charges?
- Over 3 years (2022 to 2025), McKesson's impairment charges has grown at a -17.6% compound annual growth rate (CAGR), from $175.00M to $98.00M.
- What does impairment charges mean?
- A write-down of an asset's value because it is worth less than what is recorded on the balance sheet.